Introduction: Similar to pediatric regimens, multiple doses of L-asparaginase (PEG-Asp) are being increasingly used in adults with newly diagnosed acute lymphoblastic leukemia (ALL) with promising results. One of the most common side effects of the drug in adults is high-grade hyperbilirubinemia and transaminitis. Despite being almost always reversible and may not recur, clinicians may still be reluctant to continue with PEG-Asp in patients with liver toxicity, losing the benefit from multiple doses of the drug. Case Report: We describe a case of adult ALL who developed PEG-Asp-related high grade liver toxicity. The rising hyperbilirubinemia and transaminitis rapidly and permanently reversed using the amino-acid derivative L-carnitine. This case goes in line with similar observations in animal models and humans. Conclusion:L-Carnitine may show therapeutic benefit in PEG-Asp-related hepatotoxicity and should be considered in clinical trials of the drug.

Keywords:
Asparaginase, Choleostatic, Hepatitis, L-Carnitine, Acute lymphoblastic leukemia
1.
Al-Nawakil C, Willems L, Mauprivez C, Laffy B, Benm'rad M, Tamburini J, Fontaine H, Sogni P, Terris B, Bouscary D: Successful treatment of L-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma 2014;55:1670-1674.
2.
Douer D, Aldoss I, Lunning MA, Burke PW, Ramezani L, Mark L, Vrona J, Park JH, Tallman MS, Avramis VI: Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 2014;32:905-911.
3.
Hong ES, Kim EK, Kang SM, Khang AR, Choi SH, Park KS, Jang HC, Lim S: Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol 2014;29:1449-1457.
4.
Lim CY, Jun DW, Jang SS, Cho WK, Chae JD, Jun JH: Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-alcoholic fatty liver disease. Korean J Gastroenterol 2010;55:384-389.
5.
Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Volti GL, Galvano F: L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am J Gastroenterol 2010;105:1338-1345.
6.
Perrott J, Murphy NG, Zed PJ: L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother 2010;44:1287-1293.
7.
Roesmann A, Afify M, Panse J, Eisert A, Steitz J, Tolba RH: L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy 2013;59:167-175.
8.
Sahoo S, Hart J: Histopathological Features of L-Asparaginase-Induced Liver Disease: Seminars in Liver Disease. Stuttgart, Thieme, 2003, vol 23, pp 295-299.
9.
Shrivastava A, Khan AA, Khurshid M, Kalam MA, Jain SK, Singhal PK: Recent developments in L-asparaginase discovery and its potential as anticancer agent. Crit Rev Oncol Hematol 2015, DOI: 10.1016/j.critrevonc.2015.01.002.
10.
Yapar K, Kart A, Karapehlivan M, Atakisi O, Tunca R, Erginsoy S, Citil M: Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp Toxicol Pathol 2007;59:121-128.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.